World’s first twice-a-year HIV prevention shot approved by FDA after 99.9% success
SMRTR summary
The FDA has approved Yeztugo, the world's first twice-yearly HIV prevention shot developed by Gilead Sciences. This injectable PrEP medication showed 99.9% effectiveness in clinical trials, potentially transforming HIV prevention efforts. The long-acting format could improve adherence and reduce stigma, though access challenges remain. Experts believe this breakthrough could play a crucial role in ending HIV transmission globally.
SMRTR provides this summary for quick context. The original article belongs to Interesting Engineering.
Read the original article